Genetic deletion or suppression of tau expression with antisense oligonucleotides improves seizure outcomes in animal models of genetic epilepsies (i.e., channelopathies) and chemoconvulsant models of evoked seizures (Roberson et al., 2007; DeVos et al., 2013; Holth et al., 2013; Gheyara et al., 2014; Li et al., 2014; Putra et al., 2020; Shao et al., 2022). Here, MAPT is linked to channelopathy.